Cargando…

NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA

BACKGROUNDS: Evaluation of quality of life (QOL) has been considered as an indispensable modality for assessment of treatment impact for patients with malignant brain tumor, especially glioblastoma. However, changes in patients’ QOL under clinical practice with current standard of care (SOC) have no...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamagishi, Yuki, Taku, Mikiko, Hanayama, Naomi, Saito, Kuniaki, Kobayashi, Keiichi, Yamada, Shin, Okajima, Yasutomo, Shiokawa, Yoshiaki, Nagane, Motoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213115/
http://dx.doi.org/10.1093/noajnl/vdz039.135
_version_ 1783531732561035264
author Yamagishi, Yuki
Taku, Mikiko
Hanayama, Naomi
Saito, Kuniaki
Kobayashi, Keiichi
Yamada, Shin
Okajima, Yasutomo
Shiokawa, Yoshiaki
Nagane, Motoo
author_facet Yamagishi, Yuki
Taku, Mikiko
Hanayama, Naomi
Saito, Kuniaki
Kobayashi, Keiichi
Yamada, Shin
Okajima, Yasutomo
Shiokawa, Yoshiaki
Nagane, Motoo
author_sort Yamagishi, Yuki
collection PubMed
description BACKGROUNDS: Evaluation of quality of life (QOL) has been considered as an indispensable modality for assessment of treatment impact for patients with malignant brain tumor, especially glioblastoma. However, changes in patients’ QOL under clinical practice with current standard of care (SOC) have not been clearly and routinely explored, so that solid baseline QOL data under SOC are not available for reliable comparison with those with novel treatments. Here we retrospectively examined changes in QOL during SOC in glioblastoma patients. PATIENTS AND METHODS: Patients with histologically confirmed glioblastoma treated in our institute from April 2016 to April 2019, who underwent QOL evaluations using EORTC QLQ-C-30/BN-20 were eligible. Outcomes were assessed with clinical factors including therapeutic regimens. RESULTS: Forty-two patients, median age 64 yo (25–87), male/female 26/16, were identified having longitudinal QOL data along with medical records. Median initial KPS and mini-mental state examination (MMSE) score were 70 (20–90) and 27, respectively, suggesting this cohort containing those in good performance status. In four patients whose QOL queries were answered by a family, median MMSE was 16, indicating the impaired NCF affect self-report ability. Long term survivors without progression remained at an adequate functional scale level, while those who recurred declined in functional scale after progression, often accompanied with an increase in symptom scales associated with tumor location. The domains of declined functional scales varied among patients, and there was no clear tendency associated with patients’ backgrounds such as age and gender. The functional scale level improved in most cases when the recurrent disease was successfully treated, but it gradually declined in a stepwise fashion by repeated recurrences. CONCLUSIONS: Changes in QOL in patients with glioblastoma were found to associate with disease status. The small number of patients who could be evaluated for QOL over time prevented extracting significant factors affecting QOL outcomes.
format Online
Article
Text
id pubmed-7213115
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72131152020-07-07 NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA Yamagishi, Yuki Taku, Mikiko Hanayama, Naomi Saito, Kuniaki Kobayashi, Keiichi Yamada, Shin Okajima, Yasutomo Shiokawa, Yoshiaki Nagane, Motoo Neurooncol Adv Abstracts BACKGROUNDS: Evaluation of quality of life (QOL) has been considered as an indispensable modality for assessment of treatment impact for patients with malignant brain tumor, especially glioblastoma. However, changes in patients’ QOL under clinical practice with current standard of care (SOC) have not been clearly and routinely explored, so that solid baseline QOL data under SOC are not available for reliable comparison with those with novel treatments. Here we retrospectively examined changes in QOL during SOC in glioblastoma patients. PATIENTS AND METHODS: Patients with histologically confirmed glioblastoma treated in our institute from April 2016 to April 2019, who underwent QOL evaluations using EORTC QLQ-C-30/BN-20 were eligible. Outcomes were assessed with clinical factors including therapeutic regimens. RESULTS: Forty-two patients, median age 64 yo (25–87), male/female 26/16, were identified having longitudinal QOL data along with medical records. Median initial KPS and mini-mental state examination (MMSE) score were 70 (20–90) and 27, respectively, suggesting this cohort containing those in good performance status. In four patients whose QOL queries were answered by a family, median MMSE was 16, indicating the impaired NCF affect self-report ability. Long term survivors without progression remained at an adequate functional scale level, while those who recurred declined in functional scale after progression, often accompanied with an increase in symptom scales associated with tumor location. The domains of declined functional scales varied among patients, and there was no clear tendency associated with patients’ backgrounds such as age and gender. The functional scale level improved in most cases when the recurrent disease was successfully treated, but it gradually declined in a stepwise fashion by repeated recurrences. CONCLUSIONS: Changes in QOL in patients with glioblastoma were found to associate with disease status. The small number of patients who could be evaluated for QOL over time prevented extracting significant factors affecting QOL outcomes. Oxford University Press 2019-12-16 /pmc/articles/PMC7213115/ http://dx.doi.org/10.1093/noajnl/vdz039.135 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Yamagishi, Yuki
Taku, Mikiko
Hanayama, Naomi
Saito, Kuniaki
Kobayashi, Keiichi
Yamada, Shin
Okajima, Yasutomo
Shiokawa, Yoshiaki
Nagane, Motoo
NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
title NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
title_full NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
title_fullStr NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
title_full_unstemmed NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
title_short NQPC-03 PROGNOSTIC SIGNIFICANCE OF QUALITY-OF-LIFE EVALUATION OVER TIME IN CLINICAL PRACTICE FOR PATIENTS WITH GLIOBLASTOMA
title_sort nqpc-03 prognostic significance of quality-of-life evaluation over time in clinical practice for patients with glioblastoma
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213115/
http://dx.doi.org/10.1093/noajnl/vdz039.135
work_keys_str_mv AT yamagishiyuki nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT takumikiko nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT hanayamanaomi nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT saitokuniaki nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT kobayashikeiichi nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT yamadashin nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT okajimayasutomo nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT shiokawayoshiaki nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma
AT naganemotoo nqpc03prognosticsignificanceofqualityoflifeevaluationovertimeinclinicalpracticeforpatientswithglioblastoma